PROCEPT BioRobotics Corp: management transactions · United States · SEC (Form 4)

About PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp. (ticker: PRCT) is a U.S.-listed medical device company traded on the NASDAQ market in the United States. The company is a focused player in surgical robotics, with a narrow but differentiated strategic emphasis on urology and, in particular, the treatment of benign prostatic hyperplasia (BPH), one of the most common prostate conditions in men. PROCEPT was incorporated in 2007 and is headquartered in San Jose, California, a location that reinforces its Silicon Valley identity and access to engineering, software, and medical-technology talent. ([ir.procept-biorobotics.com](https://ir.procept-biorobotics.com/investor-relations?utm_source=openai)) At the center of the business is the AQUABEAM Robotic System and its Aquablation therapy procedure. Aquablation is a minimally invasive, image-guided treatment that combines real-time ultrasound, cystoscopy, and robotic execution to remove obstructive prostate tissue in a controlled manner. PROCEPT’s commercial proposition is built around a clinically distinct value chain: it is not a broad surgical robotics platform company, but rather a category specialist focused on a single high-value urology indication. The company highlights clinical durability, symptom relief, and preservation of sexual function and continence as key differentiators versus more traditional surgical approaches. ([ir.procept-biorobotics.com](https://ir.procept-biorobotics.com/node/8641/pdf)) A major product milestone was the FDA clearance and U.S. launch of HYDROS, the next-generation AI-powered robotic system for Aquablation therapy. According to company materials, HYDROS adds AI-assisted treatment planning, enhanced image guidance, and a streamlined workflow intended to improve operating-room efficiency and surgeon experience. PROCEPT describes HYDROS as the evolution of its robotic platform and a basis for broader adoption in the U.S. market. The company also notes an expanding installed base of robotic systems in the United States, supporting recurring procedure growth over time. ([ir.procept-biorobotics.com](https://ir.procept-biorobotics.com/node/8641/pdf)) From a competitive standpoint, PROCEPT occupies a specialized niche in a market where larger surgical robotics franchises tend to focus on broader procedural categories. That specialization can be an advantage because it allows the company to build a strong clinical narrative, concentrate sales and training efforts, and target a sizable unmet need in BPH treatment. At the same time, the investment case remains dependent on adoption rates, reimbursement dynamics, physician training, and hospital capital purchasing decisions, which are all important for a commercial-stage medtech company. ([procept-biorobotics.com](https://www.procept-biorobotics.com/about-us?utm_source=openai)) Recent developments have been encouraging. In May 2026, PROCEPT said that updated American Urological Association guidelines strengthened the recommendation for Aquablation therapy, an important validation for the procedure’s clinical profile and market position. In its first-quarter 2026 results, the company reported revenue of $83.132 million, reflecting continued top-line momentum. PROCEPT has also remained active on the investor-conference circuit, underscoring management’s focus on visibility and capital-markets engagement. ([ir.procept-biorobotics.com](https://ir.procept-biorobotics.com/))